Vaccines of new coronavirus are seen as important for long term launch of Tokyo Olympics and paralympics within an year.
However it is shown in the research studies that the people infected with covid-19 have lost their immunity from infection within a few months.
The research has criticized on hope of vaccine manufacturers who have been working around to produce mass vaccinations that boost antibiotics in people against the disease.
A King’s College London study of more than 90 people infected with COVID-19 showed that the levels of antibodies peaked three weeks after the onset of symptoms, and then declined rapidly. Only about 16.7 percent of them had elevated levels of antibodies three months later. Similar findings have been reported in Spain as well.
“Antibody levels for asymptomatic individuals are low, and the antibodies in people with no or mild symptoms do not last long,” Dr. Tetsuo Nakayama, a project professor at Kitasato Institute for Life Sciences and director of the Japanese Society of Clinical Virology, said.
Dr. Barry Bloom, a professor at Harvard School of Public Health, says the data from many countries indicate that SARS-CoV-2 antibodies in patients tend to decline more rapidly than in other virus infections. “They last for sure for several months and some may last a lot longer.”
Bloom stated that the original global severe acute respiratory syndrome (SARS) outbreak occurred in 2002–2003, with some having antibodies 18 years later.
It is unclear if the antibody level is high enough to ensure safety, but even small amounts of neutralizing antibodies may be protective, Bloom said.
This situation does not look as bad as the powerful immune system composed of T cells in our blood that bind and kill infected cells – with the help of B cells that produce antibodies – on memory from previous infections. is based.
“T cells carry immunologic memory and the reintroduction of the virus could stimulate a memory response leading to rapid production of antibodies,” Bloom said.
There are many questions about the effectiveness and efficacy of vaccines in preventing coronovirus disease, but a team of scientists at Oxford University said the results of Phase I-2 trials showed that the vaccine was developed with UK biopharmacy firm AstraZeneca Is happening Cell response within 14 days of vaccination and an antibody response within 28 days.
“We saw the strongest immune response in the 10 participants who received two doses of the vaccine, indicating that this might be a good strategy for vaccination,” Professor Andrew Pollard, chief investigator for the University of Oxford COVID-19 vaccine study, said.
Nakam said vaccines could hope to pave the way for the world economy to return to normal levels and enable Japan to host the Olympic Games next year. But this is not easy to accomplish in such an easy time frame because long-term follow-up studies need to see if people who have received inoculation against the disease experience severe COVID-19 symptoms on the road a few years later .
“The successful creation of antibodies through a booster shot of the vaccines and reports of no side effects alone are not enough to provide comfort,” he said.
“There is concern that to come first, Russian authorities approve a vaccine without the necessary test data,” he said. “It is a recombinant of two adenovirus strains, so there is no reason to believe that it may not be effective and safe, but there needs to be real data.”
Related Posts
